Global Infliximab Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Infliximab Biosimilar market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Infliximab Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Infliximab Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Infliximab Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Infliximab Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Napp Pharmaceuticals Group, Janssen Biotech, Alvogen, Merck and Celltrion, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Infliximab Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Infliximab Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Infliximab Biosimilar, with price, sales, revenue and global market share of Infliximab Biosimilar from 2018 to 2023.
Chapter 3, the Infliximab Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Infliximab Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Infliximab Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Infliximab Biosimilar.
Chapter 14 and 15, to describe Infliximab Biosimilar sales channel, distributors, customers, research findings and conclusion.
This report is a detailed and comprehensive analysis for global Infliximab Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Infliximab Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Infliximab Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Infliximab Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Infliximab Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Napp Pharmaceuticals Group, Janssen Biotech, Alvogen, Merck and Celltrion, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Infliximab Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- CT-P13/infliximab-dyyb
- Remsima
- Inflectra
- Crohn's Disease
- Rheumatoid Arthritis
- Ulcerative Colitis
- Ankylosing Spondylitis
- Plaque Psoriasis
- Others
- Napp Pharmaceuticals Group
- Janssen Biotech
- Alvogen
- Merck
- Celltrion
- Pfizer(Ac Hospira)
- Nippon Kayaku
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Infliximab Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Infliximab Biosimilar, with price, sales, revenue and global market share of Infliximab Biosimilar from 2018 to 2023.
Chapter 3, the Infliximab Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Infliximab Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Infliximab Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Infliximab Biosimilar.
Chapter 14 and 15, to describe Infliximab Biosimilar sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Infliximab Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Infliximab Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 CT-P13/infliximab-dyyb
1.3.3 Remsima
1.3.4 Inflectra
1.4 Market Analysis by Application
1.4.1 Overview: Global Infliximab Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Crohn's Disease
1.4.3 Rheumatoid Arthritis
1.4.4 Ulcerative Colitis
1.4.5 Ankylosing Spondylitis
1.4.6 Plaque Psoriasis
1.4.7 Others
1.5 Global Infliximab Biosimilar Market Size & Forecast
1.5.1 Global Infliximab Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Infliximab Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Infliximab Biosimilar Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Napp Pharmaceuticals Group
2.1.1 Napp Pharmaceuticals Group Details
2.1.2 Napp Pharmaceuticals Group Major Business
2.1.3 Napp Pharmaceuticals Group Infliximab Biosimilar Product and Services
2.1.4 Napp Pharmaceuticals Group Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Napp Pharmaceuticals Group Recent Developments/Updates
2.2 Janssen Biotech
2.2.1 Janssen Biotech Details
2.2.2 Janssen Biotech Major Business
2.2.3 Janssen Biotech Infliximab Biosimilar Product and Services
2.2.4 Janssen Biotech Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Janssen Biotech Recent Developments/Updates
2.3 Alvogen
2.3.1 Alvogen Details
2.3.2 Alvogen Major Business
2.3.3 Alvogen Infliximab Biosimilar Product and Services
2.3.4 Alvogen Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Alvogen Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Infliximab Biosimilar Product and Services
2.4.4 Merck Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Merck Recent Developments/Updates
2.5 Celltrion
2.5.1 Celltrion Details
2.5.2 Celltrion Major Business
2.5.3 Celltrion Infliximab Biosimilar Product and Services
2.5.4 Celltrion Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Celltrion Recent Developments/Updates
2.6 Pfizer(Ac Hospira)
2.6.1 Pfizer(Ac Hospira) Details
2.6.2 Pfizer(Ac Hospira) Major Business
2.6.3 Pfizer(Ac Hospira) Infliximab Biosimilar Product and Services
2.6.4 Pfizer(Ac Hospira) Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer(Ac Hospira) Recent Developments/Updates
2.7 Nippon Kayaku
2.7.1 Nippon Kayaku Details
2.7.2 Nippon Kayaku Major Business
2.7.3 Nippon Kayaku Infliximab Biosimilar Product and Services
2.7.4 Nippon Kayaku Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Nippon Kayaku Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INFLIXIMAB BIOSIMILAR BY MANUFACTURER
3.1 Global Infliximab Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Infliximab Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Infliximab Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Infliximab Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Infliximab Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Infliximab Biosimilar Manufacturer Market Share in 2022
3.5 Infliximab Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Infliximab Biosimilar Market: Region Footprint
3.5.2 Infliximab Biosimilar Market: Company Product Type Footprint
3.5.3 Infliximab Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Infliximab Biosimilar Market Size by Region
4.1.1 Global Infliximab Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Infliximab Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Infliximab Biosimilar Average Price by Region (2018-2029)
4.2 North America Infliximab Biosimilar Consumption Value (2018-2029)
4.3 Europe Infliximab Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Infliximab Biosimilar Consumption Value (2018-2029)
4.5 South America Infliximab Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Infliximab Biosimilar Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Infliximab Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Infliximab Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Infliximab Biosimilar Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Infliximab Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Infliximab Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Infliximab Biosimilar Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Infliximab Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Infliximab Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Infliximab Biosimilar Market Size by Country
7.3.1 North America Infliximab Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Infliximab Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Infliximab Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Infliximab Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Infliximab Biosimilar Market Size by Country
8.3.1 Europe Infliximab Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Infliximab Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Infliximab Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Infliximab Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Infliximab Biosimilar Market Size by Region
9.3.1 Asia-Pacific Infliximab Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Infliximab Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Infliximab Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Infliximab Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Infliximab Biosimilar Market Size by Country
10.3.1 South America Infliximab Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Infliximab Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Infliximab Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Infliximab Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Infliximab Biosimilar Market Size by Country
11.3.1 Middle East & Africa Infliximab Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Infliximab Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Infliximab Biosimilar Market Drivers
12.2 Infliximab Biosimilar Market Restraints
12.3 Infliximab Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Infliximab Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Infliximab Biosimilar
13.3 Infliximab Biosimilar Production Process
13.4 Infliximab Biosimilar Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Infliximab Biosimilar Typical Distributors
14.3 Infliximab Biosimilar Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Infliximab Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Infliximab Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 CT-P13/infliximab-dyyb
1.3.3 Remsima
1.3.4 Inflectra
1.4 Market Analysis by Application
1.4.1 Overview: Global Infliximab Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Crohn's Disease
1.4.3 Rheumatoid Arthritis
1.4.4 Ulcerative Colitis
1.4.5 Ankylosing Spondylitis
1.4.6 Plaque Psoriasis
1.4.7 Others
1.5 Global Infliximab Biosimilar Market Size & Forecast
1.5.1 Global Infliximab Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Infliximab Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Infliximab Biosimilar Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Napp Pharmaceuticals Group
2.1.1 Napp Pharmaceuticals Group Details
2.1.2 Napp Pharmaceuticals Group Major Business
2.1.3 Napp Pharmaceuticals Group Infliximab Biosimilar Product and Services
2.1.4 Napp Pharmaceuticals Group Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Napp Pharmaceuticals Group Recent Developments/Updates
2.2 Janssen Biotech
2.2.1 Janssen Biotech Details
2.2.2 Janssen Biotech Major Business
2.2.3 Janssen Biotech Infliximab Biosimilar Product and Services
2.2.4 Janssen Biotech Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Janssen Biotech Recent Developments/Updates
2.3 Alvogen
2.3.1 Alvogen Details
2.3.2 Alvogen Major Business
2.3.3 Alvogen Infliximab Biosimilar Product and Services
2.3.4 Alvogen Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Alvogen Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Infliximab Biosimilar Product and Services
2.4.4 Merck Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Merck Recent Developments/Updates
2.5 Celltrion
2.5.1 Celltrion Details
2.5.2 Celltrion Major Business
2.5.3 Celltrion Infliximab Biosimilar Product and Services
2.5.4 Celltrion Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Celltrion Recent Developments/Updates
2.6 Pfizer(Ac Hospira)
2.6.1 Pfizer(Ac Hospira) Details
2.6.2 Pfizer(Ac Hospira) Major Business
2.6.3 Pfizer(Ac Hospira) Infliximab Biosimilar Product and Services
2.6.4 Pfizer(Ac Hospira) Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Pfizer(Ac Hospira) Recent Developments/Updates
2.7 Nippon Kayaku
2.7.1 Nippon Kayaku Details
2.7.2 Nippon Kayaku Major Business
2.7.3 Nippon Kayaku Infliximab Biosimilar Product and Services
2.7.4 Nippon Kayaku Infliximab Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Nippon Kayaku Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INFLIXIMAB BIOSIMILAR BY MANUFACTURER
3.1 Global Infliximab Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Infliximab Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Infliximab Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Infliximab Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Infliximab Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Infliximab Biosimilar Manufacturer Market Share in 2022
3.5 Infliximab Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Infliximab Biosimilar Market: Region Footprint
3.5.2 Infliximab Biosimilar Market: Company Product Type Footprint
3.5.3 Infliximab Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Infliximab Biosimilar Market Size by Region
4.1.1 Global Infliximab Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Infliximab Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Infliximab Biosimilar Average Price by Region (2018-2029)
4.2 North America Infliximab Biosimilar Consumption Value (2018-2029)
4.3 Europe Infliximab Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Infliximab Biosimilar Consumption Value (2018-2029)
4.5 South America Infliximab Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Infliximab Biosimilar Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Infliximab Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Infliximab Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Infliximab Biosimilar Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Infliximab Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Infliximab Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Infliximab Biosimilar Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Infliximab Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Infliximab Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Infliximab Biosimilar Market Size by Country
7.3.1 North America Infliximab Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Infliximab Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Infliximab Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Infliximab Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Infliximab Biosimilar Market Size by Country
8.3.1 Europe Infliximab Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Infliximab Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Infliximab Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Infliximab Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Infliximab Biosimilar Market Size by Region
9.3.1 Asia-Pacific Infliximab Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Infliximab Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Infliximab Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Infliximab Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Infliximab Biosimilar Market Size by Country
10.3.1 South America Infliximab Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Infliximab Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Infliximab Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Infliximab Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Infliximab Biosimilar Market Size by Country
11.3.1 Middle East & Africa Infliximab Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Infliximab Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Infliximab Biosimilar Market Drivers
12.2 Infliximab Biosimilar Market Restraints
12.3 Infliximab Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Infliximab Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Infliximab Biosimilar
13.3 Infliximab Biosimilar Production Process
13.4 Infliximab Biosimilar Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Infliximab Biosimilar Typical Distributors
14.3 Infliximab Biosimilar Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Infliximab Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Infliximab Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Napp Pharmaceuticals Group Basic Information, Manufacturing Base and Competitors
Table 4. Napp Pharmaceuticals Group Major Business
Table 5. Napp Pharmaceuticals Group Infliximab Biosimilar Product and Services
Table 6. Napp Pharmaceuticals Group Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Napp Pharmaceuticals Group Recent Developments/Updates
Table 8. Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table 9. Janssen Biotech Major Business
Table 10. Janssen Biotech Infliximab Biosimilar Product and Services
Table 11. Janssen Biotech Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Janssen Biotech Recent Developments/Updates
Table 13. Alvogen Basic Information, Manufacturing Base and Competitors
Table 14. Alvogen Major Business
Table 15. Alvogen Infliximab Biosimilar Product and Services
Table 16. Alvogen Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Alvogen Recent Developments/Updates
Table 18. Merck Basic Information, Manufacturing Base and Competitors
Table 19. Merck Major Business
Table 20. Merck Infliximab Biosimilar Product and Services
Table 21. Merck Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Merck Recent Developments/Updates
Table 23. Celltrion Basic Information, Manufacturing Base and Competitors
Table 24. Celltrion Major Business
Table 25. Celltrion Infliximab Biosimilar Product and Services
Table 26. Celltrion Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Celltrion Recent Developments/Updates
Table 28. Pfizer(Ac Hospira) Basic Information, Manufacturing Base and Competitors
Table 29. Pfizer(Ac Hospira) Major Business
Table 30. Pfizer(Ac Hospira) Infliximab Biosimilar Product and Services
Table 31. Pfizer(Ac Hospira) Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Pfizer(Ac Hospira) Recent Developments/Updates
Table 33. Nippon Kayaku Basic Information, Manufacturing Base and Competitors
Table 34. Nippon Kayaku Major Business
Table 35. Nippon Kayaku Infliximab Biosimilar Product and Services
Table 36. Nippon Kayaku Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Nippon Kayaku Recent Developments/Updates
Table 38. Global Infliximab Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 39. Global Infliximab Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 40. Global Infliximab Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 41. Market Position of Manufacturers in Infliximab Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 42. Head Office and Infliximab Biosimilar Production Site of Key Manufacturer
Table 43. Infliximab Biosimilar Market: Company Product Type Footprint
Table 44. Infliximab Biosimilar Market: Company Product Application Footprint
Table 45. Infliximab Biosimilar New Market Entrants and Barriers to Market Entry
Table 46. Infliximab Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Infliximab Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 48. Global Infliximab Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 49. Global Infliximab Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 50. Global Infliximab Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 51. Global Infliximab Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 52. Global Infliximab Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 53. Global Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 54. Global Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 55. Global Infliximab Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Global Infliximab Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Global Infliximab Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 58. Global Infliximab Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 59. Global Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 60. Global Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 61. Global Infliximab Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 62. Global Infliximab Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 63. Global Infliximab Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 64. Global Infliximab Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 65. North America Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 66. North America Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 67. North America Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 68. North America Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 69. North America Infliximab Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 70. North America Infliximab Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 71. North America Infliximab Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 72. North America Infliximab Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Europe Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 74. Europe Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 75. Europe Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 76. Europe Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 77. Europe Infliximab Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 78. Europe Infliximab Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 79. Europe Infliximab Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Infliximab Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 82. Asia-Pacific Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 83. Asia-Pacific Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 84. Asia-Pacific Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 85. Asia-Pacific Infliximab Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 86. Asia-Pacific Infliximab Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 87. Asia-Pacific Infliximab Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 88. Asia-Pacific Infliximab Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 89. South America Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 90. South America Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 91. South America Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 92. South America Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 93. South America Infliximab Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 94. South America Infliximab Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 95. South America Infliximab Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 96. South America Infliximab Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 97. Middle East & Africa Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 98. Middle East & Africa Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 99. Middle East & Africa Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Middle East & Africa Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Middle East & Africa Infliximab Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 102. Middle East & Africa Infliximab Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 103. Middle East & Africa Infliximab Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 104. Middle East & Africa Infliximab Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 105. Infliximab Biosimilar Raw Material
Table 106. Key Manufacturers of Infliximab Biosimilar Raw Materials
Table 107. Infliximab Biosimilar Typical Distributors
Table 108. Infliximab Biosimilar Typical Customers
Table 1. Global Infliximab Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Infliximab Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Napp Pharmaceuticals Group Basic Information, Manufacturing Base and Competitors
Table 4. Napp Pharmaceuticals Group Major Business
Table 5. Napp Pharmaceuticals Group Infliximab Biosimilar Product and Services
Table 6. Napp Pharmaceuticals Group Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Napp Pharmaceuticals Group Recent Developments/Updates
Table 8. Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table 9. Janssen Biotech Major Business
Table 10. Janssen Biotech Infliximab Biosimilar Product and Services
Table 11. Janssen Biotech Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Janssen Biotech Recent Developments/Updates
Table 13. Alvogen Basic Information, Manufacturing Base and Competitors
Table 14. Alvogen Major Business
Table 15. Alvogen Infliximab Biosimilar Product and Services
Table 16. Alvogen Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Alvogen Recent Developments/Updates
Table 18. Merck Basic Information, Manufacturing Base and Competitors
Table 19. Merck Major Business
Table 20. Merck Infliximab Biosimilar Product and Services
Table 21. Merck Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Merck Recent Developments/Updates
Table 23. Celltrion Basic Information, Manufacturing Base and Competitors
Table 24. Celltrion Major Business
Table 25. Celltrion Infliximab Biosimilar Product and Services
Table 26. Celltrion Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Celltrion Recent Developments/Updates
Table 28. Pfizer(Ac Hospira) Basic Information, Manufacturing Base and Competitors
Table 29. Pfizer(Ac Hospira) Major Business
Table 30. Pfizer(Ac Hospira) Infliximab Biosimilar Product and Services
Table 31. Pfizer(Ac Hospira) Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Pfizer(Ac Hospira) Recent Developments/Updates
Table 33. Nippon Kayaku Basic Information, Manufacturing Base and Competitors
Table 34. Nippon Kayaku Major Business
Table 35. Nippon Kayaku Infliximab Biosimilar Product and Services
Table 36. Nippon Kayaku Infliximab Biosimilar Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Nippon Kayaku Recent Developments/Updates
Table 38. Global Infliximab Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 39. Global Infliximab Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)
Table 40. Global Infliximab Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 41. Market Position of Manufacturers in Infliximab Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 42. Head Office and Infliximab Biosimilar Production Site of Key Manufacturer
Table 43. Infliximab Biosimilar Market: Company Product Type Footprint
Table 44. Infliximab Biosimilar Market: Company Product Application Footprint
Table 45. Infliximab Biosimilar New Market Entrants and Barriers to Market Entry
Table 46. Infliximab Biosimilar Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Infliximab Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 48. Global Infliximab Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 49. Global Infliximab Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 50. Global Infliximab Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 51. Global Infliximab Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 52. Global Infliximab Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 53. Global Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 54. Global Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 55. Global Infliximab Biosimilar Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Global Infliximab Biosimilar Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Global Infliximab Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 58. Global Infliximab Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 59. Global Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 60. Global Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 61. Global Infliximab Biosimilar Consumption Value by Application (2018-2023) & (USD Million)
Table 62. Global Infliximab Biosimilar Consumption Value by Application (2024-2029) & (USD Million)
Table 63. Global Infliximab Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 64. Global Infliximab Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 65. North America Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 66. North America Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 67. North America Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 68. North America Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 69. North America Infliximab Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 70. North America Infliximab Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 71. North America Infliximab Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 72. North America Infliximab Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Europe Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 74. Europe Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 75. Europe Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 76. Europe Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 77. Europe Infliximab Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 78. Europe Infliximab Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 79. Europe Infliximab Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Infliximab Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 82. Asia-Pacific Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 83. Asia-Pacific Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 84. Asia-Pacific Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 85. Asia-Pacific Infliximab Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 86. Asia-Pacific Infliximab Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 87. Asia-Pacific Infliximab Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 88. Asia-Pacific Infliximab Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 89. South America Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 90. South America Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 91. South America Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 92. South America Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 93. South America Infliximab Biosimilar Sales Quantity by Country (2018-2023) & (K Units)
Table 94. South America Infliximab Biosimilar Sales Quantity by Country (2024-2029) & (K Units)
Table 95. South America Infliximab Biosimilar Consumption Value by Country (2018-2023) & (USD Million)
Table 96. South America Infliximab Biosimilar Consumption Value by Country (2024-2029) & (USD Million)
Table 97. Middle East & Africa Infliximab Biosimilar Sales Quantity by Type (2018-2023) & (K Units)
Table 98. Middle East & Africa Infliximab Biosimilar Sales Quantity by Type (2024-2029) & (K Units)
Table 99. Middle East & Africa Infliximab Biosimilar Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Middle East & Africa Infliximab Biosimilar Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Middle East & Africa Infliximab Biosimilar Sales Quantity by Region (2018-2023) & (K Units)
Table 102. Middle East & Africa Infliximab Biosimilar Sales Quantity by Region (2024-2029) & (K Units)
Table 103. Middle East & Africa Infliximab Biosimilar Consumption Value by Region (2018-2023) & (USD Million)
Table 104. Middle East & Africa Infliximab Biosimilar Consumption Value by Region (2024-2029) & (USD Million)
Table 105. Infliximab Biosimilar Raw Material
Table 106. Key Manufacturers of Infliximab Biosimilar Raw Materials
Table 107. Infliximab Biosimilar Typical Distributors
Table 108. Infliximab Biosimilar Typical Customers
LIST OF FIGURES
Figure 1. Infliximab Biosimilar Picture
Figure 2. Global Infliximab Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Infliximab Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. CT-P13/infliximab-dyyb Examples
Figure 5. Remsima Examples
Figure 6. Inflectra Examples
Figure 7. Global Infliximab Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Infliximab Biosimilar Consumption Value Market Share by Application in 2022
Figure 9. Crohn's Disease Examples
Figure 10. Rheumatoid Arthritis Examples
Figure 11. Ulcerative Colitis Examples
Figure 12. Ankylosing Spondylitis Examples
Figure 13. Plaque Psoriasis Examples
Figure 14. Others Examples
Figure 15. Global Infliximab Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Infliximab Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Infliximab Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 18. Global Infliximab Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 19. Global Infliximab Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 20. Global Infliximab Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 21. Producer Shipments of Infliximab Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 22. Top 3 Infliximab Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Top 6 Infliximab Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Global Infliximab Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 25. Global Infliximab Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 26. North America Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 27. Europe Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 28. Asia-Pacific Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 29. South America Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 30. Middle East & Africa Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 31. Global Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 32. Global Infliximab Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 33. Global Infliximab Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 34. Global Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 35. Global Infliximab Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 36. Global Infliximab Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 37. North America Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 38. North America Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 39. North America Infliximab Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 40. North America Infliximab Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 41. United States Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Canada Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Mexico Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Europe Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 45. Europe Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 46. Europe Infliximab Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 47. Europe Infliximab Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 48. Germany Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. France Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. United Kingdom Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Russia Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Italy Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Asia-Pacific Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 54. Asia-Pacific Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 55. Asia-Pacific Infliximab Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 56. Asia-Pacific Infliximab Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 57. China Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Japan Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Korea Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. India Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Southeast Asia Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Australia Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. South America Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 64. South America Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 65. South America Infliximab Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 66. South America Infliximab Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 67. Brazil Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Argentina Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Middle East & Africa Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 70. Middle East & Africa Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 71. Middle East & Africa Infliximab Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 72. Middle East & Africa Infliximab Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 73. Turkey Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Egypt Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Saudi Arabia Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. South Africa Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Infliximab Biosimilar Market Drivers
Figure 78. Infliximab Biosimilar Market Restraints
Figure 79. Infliximab Biosimilar Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Infliximab Biosimilar in 2022
Figure 82. Manufacturing Process Analysis of Infliximab Biosimilar
Figure 83. Infliximab Biosimilar Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
Figure 1. Infliximab Biosimilar Picture
Figure 2. Global Infliximab Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Infliximab Biosimilar Consumption Value Market Share by Type in 2022
Figure 4. CT-P13/infliximab-dyyb Examples
Figure 5. Remsima Examples
Figure 6. Inflectra Examples
Figure 7. Global Infliximab Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Infliximab Biosimilar Consumption Value Market Share by Application in 2022
Figure 9. Crohn's Disease Examples
Figure 10. Rheumatoid Arthritis Examples
Figure 11. Ulcerative Colitis Examples
Figure 12. Ankylosing Spondylitis Examples
Figure 13. Plaque Psoriasis Examples
Figure 14. Others Examples
Figure 15. Global Infliximab Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Infliximab Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Infliximab Biosimilar Sales Quantity (2018-2029) & (K Units)
Figure 18. Global Infliximab Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 19. Global Infliximab Biosimilar Sales Quantity Market Share by Manufacturer in 2022
Figure 20. Global Infliximab Biosimilar Consumption Value Market Share by Manufacturer in 2022
Figure 21. Producer Shipments of Infliximab Biosimilar by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 22. Top 3 Infliximab Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Top 6 Infliximab Biosimilar Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Global Infliximab Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 25. Global Infliximab Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 26. North America Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 27. Europe Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 28. Asia-Pacific Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 29. South America Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 30. Middle East & Africa Infliximab Biosimilar Consumption Value (2018-2029) & (USD Million)
Figure 31. Global Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 32. Global Infliximab Biosimilar Consumption Value Market Share by Type (2018-2029)
Figure 33. Global Infliximab Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 34. Global Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 35. Global Infliximab Biosimilar Consumption Value Market Share by Application (2018-2029)
Figure 36. Global Infliximab Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 37. North America Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 38. North America Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 39. North America Infliximab Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 40. North America Infliximab Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 41. United States Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Canada Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Mexico Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Europe Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 45. Europe Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 46. Europe Infliximab Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 47. Europe Infliximab Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 48. Germany Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. France Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. United Kingdom Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Russia Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Italy Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Asia-Pacific Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 54. Asia-Pacific Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 55. Asia-Pacific Infliximab Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 56. Asia-Pacific Infliximab Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 57. China Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Japan Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Korea Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. India Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Southeast Asia Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Australia Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. South America Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 64. South America Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 65. South America Infliximab Biosimilar Sales Quantity Market Share by Country (2018-2029)
Figure 66. South America Infliximab Biosimilar Consumption Value Market Share by Country (2018-2029)
Figure 67. Brazil Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Argentina Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Middle East & Africa Infliximab Biosimilar Sales Quantity Market Share by Type (2018-2029)
Figure 70. Middle East & Africa Infliximab Biosimilar Sales Quantity Market Share by Application (2018-2029)
Figure 71. Middle East & Africa Infliximab Biosimilar Sales Quantity Market Share by Region (2018-2029)
Figure 72. Middle East & Africa Infliximab Biosimilar Consumption Value Market Share by Region (2018-2029)
Figure 73. Turkey Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Egypt Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Saudi Arabia Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. South Africa Infliximab Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Infliximab Biosimilar Market Drivers
Figure 78. Infliximab Biosimilar Market Restraints
Figure 79. Infliximab Biosimilar Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Infliximab Biosimilar in 2022
Figure 82. Manufacturing Process Analysis of Infliximab Biosimilar
Figure 83. Infliximab Biosimilar Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
